Abbreviated 510(k) program would shift work from ODE to FDA inspectors, agency staffers say.
This article was originally published in The Gray Sheet
Executive SummaryFDA'S ABBREVIATED 510(k) PLAN WOULD PUT BURDEN ON FIELD INSPECTORS to monitor manufacturers' compliance with standards cited in the premarket submissions, agency staffers say. Under the abbreviated 510(k) plan being developed by the agency, firms would be able to certify conformance of devices to relevant standards rather than submitting data covered by the standard as part of a 510(k) ("The Gray Sheet" June 23, p. 5). Data proving conformance would be kept in-house by manufacturers.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.